BACKGROUND: Fertility drugs stimulate hyperovulation, which may have implications for breast cancer. We examined the association between use of fertility drugs (clomiphene citrate [CC] and follicle-stimulating hormone [FSH]) and subsequent risk of young-onset (<50 years at diagnosis) breast cancer. METHODS: We conducted the Two Sister Study, a sister-matched case-control study, by enrolling 1422 women between September 2008 and December 2010, who were younger than age 50 years at diagnosis with breast cancer and were enrolled within 4 years of diagnosis, and 1669 breast cancer-free control sisters from the Sister Study. Participants reported their use of fertility drugs (CC and FSH) and ever-users reported whether a pregnancy had resulted that lasted 10 or more (10+) weeks. Conditional logistic regression was used to estimate confounder-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for fertility drug use with or without conception of a 10+ week pregnancy. RESULTS: A total of 288 participants reported having used ovulation-stimulating drugs (193 CC only, 29 FSH only, and 66 both). Overall, women who had used fertility drugs showed a non-statistically significantly decreased risk of breast cancer, compared with nonusers (OR = 0.82, 95% CI = 0.63 to 1.08). Women who had used fertility drugs but had not conceived a 10+ week pregnancy under treatment showed a statistically significantly decreased risk of breast cancer compared with nonusers (OR = 0.62, 95% CI = 0.43 to 0.89). Women who had used fertility drugs and conceived a 10+ week pregnancy under treatment showed a statistically significantly increased risk of breast cancer compared with unsuccessfully treated women (OR = 1.82, 95% CI = 1.10 to 3.00), although their risk was not increased compared with women who had not used fertility drugs (OR = 1.13, 95% CI = 0.78 to 1.64). CONCLUSIONS: In the absence of a 10+ week pregnancy under treatment, exposure to ovulation-stimulating fertility drugs was associated with reduced risk of young-onset breast cancer. This apparent association was absent in women who conceived a 10+ week pregnancy under treatment, for whom risk was higher than that of unsuccessfully treated women, but similar to that of untreated women.
BACKGROUND: Fertility drugs stimulate hyperovulation, which may have implications for breast cancer. We examined the association between use of fertility drugs (clomiphene citrate [CC] and follicle-stimulating hormone [FSH]) and subsequent risk of young-onset (<50 years at diagnosis) breast cancer. METHODS: We conducted the Two Sister Study, a sister-matched case-control study, by enrolling 1422 women between September 2008 and December 2010, who were younger than age 50 years at diagnosis with breast cancer and were enrolled within 4 years of diagnosis, and 1669 breast cancer-free control sisters from the Sister Study. Participants reported their use of fertility drugs (CC and FSH) and ever-users reported whether a pregnancy had resulted that lasted 10 or more (10+) weeks. Conditional logistic regression was used to estimate confounder-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for fertility drug use with or without conception of a 10+ week pregnancy. RESULTS: A total of 288 participants reported having used ovulation-stimulating drugs (193 CC only, 29 FSH only, and 66 both). Overall, women who had used fertility drugs showed a non-statistically significantly decreased risk of breast cancer, compared with nonusers (OR = 0.82, 95% CI = 0.63 to 1.08). Women who had used fertility drugs but had not conceived a 10+ week pregnancy under treatment showed a statistically significantly decreased risk of breast cancer compared with nonusers (OR = 0.62, 95% CI = 0.43 to 0.89). Women who had used fertility drugs and conceived a 10+ week pregnancy under treatment showed a statistically significantly increased risk of breast cancer compared with unsuccessfully treated women (OR = 1.82, 95% CI = 1.10 to 3.00), although their risk was not increased compared with women who had not used fertility drugs (OR = 1.13, 95% CI = 0.78 to 1.64). CONCLUSIONS: In the absence of a 10+ week pregnancy under treatment, exposure to ovulation-stimulating fertility drugs was associated with reduced risk of young-onset breast cancer. This apparent association was absent in women who conceived a 10+ week pregnancy under treatment, for whom risk was higher than that of unsuccessfully treated women, but similar to that of untreated women.
Authors: Ronald T Burkman; Mei-Tzu C Tang; Kathleen E Malone; Polly A Marchbanks; Jill A McDonald; Suzanne G Folger; Sandra A Norman; Brian L Strom; Leslie Bernstein; Giske Ursin; Linda K Weiss; Janet R Daling; Michael S Simon; Robert Spirtas Journal: Fertil Steril Date: 2003-04 Impact factor: 7.329
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Louise A Brinton; Bert Scoccia; Kamran S Moghissi; Carolyn L Westhoff; Michelle D Althuis; Jerome E Mabie; Emmet J Lamb Journal: Hum Reprod Date: 2004-06-24 Impact factor: 6.918
Authors: Angeline S Andrew; Katie M O'Brien; Brian P Jackson; Dale P Sandler; Wendy E Kaye; Laurie Wagner; Elijah W Stommel; D Kevin Horton; Paul Mehta; Clarice R Weinberg Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2020-04-24 Impact factor: 4.092
Authors: Ming-Fen Ho; Cristina Correia; James N Ingle; Rima Kaddurah-Daouk; Liewei Wang; Scott H Kaufmann; Richard M Weinshilboum Journal: Biochem Pharmacol Date: 2018-04-03 Impact factor: 5.858
Authors: Katie M O'Brien; Chunyuan Fei; Dale P Sandler; Hazel B Nichols; Lisa A DeRoo; Clarice R Weinberg Journal: Am J Epidemiol Date: 2015-02-18 Impact factor: 4.897
Authors: Katie M O'Brien; Alexandra J White; Brian P Jackson; Margaret R Karagas; Dale P Sandler; Clarice R Weinberg Journal: Am J Epidemiol Date: 2019-04-01 Impact factor: 4.897
Authors: Katie M O'Brien; Alexandra J White; Brian P Jackson; Margaret R Karagas; Dale P Sandler; Clarice R Weinberg Journal: Am J Epidemiol Date: 2019-11-01 Impact factor: 4.897
Authors: Natasha D Buchanan; Sabitha Dasari; Juan L Rodriguez; Judith Lee Smith; M Elizabeth Hodgson; Clarice R Weinberg; Dale P Sandler Journal: Am J Prev Med Date: 2015-12 Impact factor: 5.043